Abstract
In this issue of Blood, Thangavelu et al have developed a novel pharmacological approach to inhibit graft-versus-host disease (GVHD) by activating retinoid X receptor (RXR) in donor T cells.
MeSH terms
-
Graft vs Host Disease* / prevention & control
-
Hematopoietic Stem Cell Transplantation*
-
Humans